Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07133490 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

INTERACT Stomach-II

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 49 to 55 · Study sites: 0 to 3v2 Show 2 more changesShow less
    • Enrollment target: 49 to 55
    • Study sites: 0 to 3
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 55 patients will take part. The aim is to test whether a new combination treatment is feasible for patients with gastric peritoneal metastases (PM). The treatment includes chemotherapy (intraperitoneal irinotecan and standard systemic therapy such as CAPOX or FOLFOX), and may also include nivolumab or trastuzumab, depending on biomarker results.
Trial Details
NCT Number NCT07133490
Lead Sponsor Erasmus Medical Center
Collaborators: Catharina Ziekenhuis Eindhoven, The Netherlands Cancer Institute
Conditions Peritoneal Metastases From Gastric Cancer
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov